LAVA Therapeutics N.V.
LVTX
$1.28
$0.043.23%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 60.86% | -7.93% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -27.46% | 20.55% | |||
| Operating Income | 71.68% | -20.55% | |||
| Income Before Tax | 70.57% | -48.58% | |||
| Income Tax Expenses | 295.83% | 12.94% | |||
| Earnings from Continuing Operations | 67.71% | -48.22% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 67.71% | -48.22% | |||
| EBIT | 71.68% | -20.55% | |||
| EBITDA | 72.16% | -20.86% | |||
| EPS Basic | 67.73% | -48.08% | |||
| Normalized Basic EPS | 102.54% | -48.46% | |||
| EPS Diluted | 67.73% | -48.08% | |||
| Normalized Diluted EPS | 102.54% | -48.46% | |||
| Average Basic Shares Outstanding | 0.08% | 0.09% | |||
| Average Diluted Shares Outstanding | 0.08% | 0.09% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||